Possible Drug-drug Interaction between Pregabalin and Clozapine in Patients with Schizophrenia: Clinical Perspectives

Abstract

Introduction: Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder. Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment.

Methods: Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms.

Results: Both patients experienced falls and consequently bone fractures. Increased plasma levels of clozapine likely contributed to the outcome. One patient had confirmed seizures whereas the mechanism in the other patient was less clear.

Discussion: This short report discusses the possible mechanism of a pregabalin-clozapine interaction.

Key words

pregabalin - clozapine - side effects - schizophrenia - anxiety

• References

• 1 Uggerby P, Nielsen RE, Correll CU et al. Characteristics and predictors of long-term institutionalization in patients with schizophrenia. Schizophr Res 2011; 131: 120-126
• 2 van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-645
• 3 Achim AM, Maziade M, Raymond E et al. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2011; 37: 811-821
• 4 Huppert JD, Weiss KA, Lim R et al. Quality of life in schizophrenia: Contributions of anxiety and depression. Schizophr Res 2001; 51: 171-180
• 5 Michail M, Birchwood M. Social anxiety disorder in first-episode psychosis: Incidence, phenomenology and relationship with paranoia. The British Journal of Psychiatry 2009; 195: 234-241
• 6 Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry 2004; 45: 460-468
• 7 Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 2007; 40: 163-168
• 8 Schönfeldt-Lecuona C, Wolf RC, Osterfeld ND et al. Pregabalin in the treatment of schizophrenic anxiety. Pharmacopsychiatry 2009; 42: 124-125
• 9 Englisch S, Esser A, Enning F et al. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 2010; 30: 437-440
• 10 Nielsen J, Correll CU, Manu P et al. Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided?. J Clin Psychiatry 2013; 74: 603-613
• 11 Nielsen J, Damkier P, Lublin H et al. Optimizing clozapine treatment. Acta Psychiatr Scand 2011; 123: 411-422
• 12 Gahr M, Schmid MM, Schönfeldt-Lecuona C. Pregabalin-associated elevation of clozapine serum levels. Pharmacopsychiatry 2012; 45: 297-299
• 13 Englisch S, Alm B, Meyer-Lindenberg A et al. Pregabalin-associated increase of clozapine serum levels. J Clin Psychopharmacol 2012; 32: 127
• 14 Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
• 15 Millar J, Sadasivan S, Weatherup N et al. Lyrica nights – recreational pregabalin abuse in an urban emergency department. Emergency Medicine Journal 2013; 30: 874
• 16 Loftus H, Wright A. Potential misuse of pregabalin and gabapentin. BMJ 2014; 348: 1290
• 17 Grosshans M, Lemenager T, Vollmert C et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol 2013; 69: 2021-2025
• 18 Grosshans MF. Pregabalin abuse, dependence, and withdrawal: A case report. Am J Psychiatry 2010; 167: 869
• 19 Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc 2010; 110: 605-607
• 20 Wills B, Reynolds P, Chu E et al. Clinical outcomes in newer anticonvulsant overdose: A poison center observational study. J Med Toxicol 2014;
• 21 Duan JZ. Applications of population pharmacokinetics in current drug labelling. J Clin Pharm Ther 2007; 32: 57-79
• 22 Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 (Suppl. 06) 13-18
• 23 Maines LW, Antonetti DA, Wolpert EB et al. Evaluation of the role of p-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 2005; 49: 610-617
• 24 Giacomini KM, Huang S-M, Tweedie DJ et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236
• 25 Wang M, Hou R, Jian J et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: A 12-month prospective study. Human Psychopharmacology: Clinical and Experimental 2014; 29: 183-189
• 26 Sørensen HJ, Jensen SOW, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: A population-based analysis. Eur Neuropsychopharmacol 2013; 23: 872-878